Bećarević Mirjana
Medical Faculty, Department of Pharmacy, University of Novi Sad, Hajduk Veljkova 3, Novi Sad, 21000, Serbia.
Curr Rheumatol Rep. 2017 Jul;19(7):40. doi: 10.1007/s11926-017-0669-1.
Laboratory criterion for the diagnosis of antiphospholipid syndrome (APS) is the presence of antiphospholipid antibodies (aPL Abs). Complement system has a role in mediating aPL Abs-induced thrombosis in animal models. The importance of antibodies against complement components (potential biomarkers of APS) and the importance of antibodies with beneficial anti-complement effects in APS (as biopharmaceuticals) are reviewed.
Antibodies against complement components described in APS patients, so far, are anti-C1q and anti-factor H Abs, although anti-factor B Abs and anti-C5a Abs were described in animal models of APS. Clinical studies in APS patients are limited to a small number of case reports. Studies that would confirm potential role of Abs against complement components (as potential biomarkers of APS) are lacking. Lack of randomized clinical trials (that would provide complete data for confirmation of beneficial effects of biopharmaceuticals in complement inhibition) in APS is alarming.
抗磷脂综合征（APS）诊断的实验室标准是存在抗磷脂抗体（aPL Abs）。在动物模型中，补体系统在介导aPL Abs诱导的血栓形成中起作用。本文综述了抗补体成分抗体（APS的潜在生物标志物）的重要性以及具有有益抗补体作用的抗体在APS中作为生物药物的重要性。
迄今为止，在APS患者中描述的抗补体成分抗体是抗C1q和抗因子H抗体，尽管在APS动物模型中描述了抗因子B抗体和抗C5a抗体。对APS患者的临床研究仅限于少数病例报告。缺乏能够证实抗补体成分抗体（作为APS的潜在生物标志物）潜在作用的研究。APS缺乏随机临床试验（可为确认生物药物在补体抑制中的有益作用提供完整数据）令人担忧。
